No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Medecine et Maladies Infectieuses

Volumn 50, Issue 4, 2020, Pages 384-

  Molina, J M ^a,b   Delaugerre, C ^a,b   Le Goff, J ^a,b   Mela Lima, B ^a   Ponscarme, D ^a   Goldwirt, L ^a   de Castro, N ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; HYDROXYCHLOROQUINE; OXYGEN; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL ACTIVITY; BODY TEMPERATURE; CLINICAL ARTICLE; COMORBIDITY; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; FRANCE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; LENGTH OF STAY; LETTER; MALE; MIDDLE AGED; MORTALITY; OBESITY; OXYGEN THERAPY; POLYMERASE CHAIN REACTION; QT PROLONGATION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SOLID MALIGNANT NEOPLASM; THROAT CULTURE; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS REPLICATION; YOUNG ADULT; BETACORONAVIRUS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONAVIRUS INFECTION; ISOLATION AND PURIFICATION; PANDEMIC; VIRUS PNEUMONIA;

ADULT; AGED; ANTIVIRAL AGENTS; AZITHROMYCIN; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85083233845     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2020.03.006     Document Type: Letter

References (8)

1. Wang, M., Cao, R., Zhang, L., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30 (2020), 269–271.
2. Al-Bari, A.A., Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect, 5, 2017, e00293.
3. Gautret, P., Lagier, J.C., Parola, P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomised clinical trial. Int J Antimicrob Agents, 2020 [ahead of print].
4. Chen, J., Liu, D., Lui, L., et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 COVID-19). J Zhejiang Univ Sci, 03, 2020, 03-.
5. Roques, P., Thiberville, S.D., Dupuis-Maguiraga, L., et al. Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection. Viruses, 10, 2018, 268.
6. Tricou, V., Minh, N.N., Van, T.P., et al. A randomised controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLos Neglected Trop Dis, 4, 2010, e785.
7. Paton, N.I., Lee, L., Xu, Y., et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 11 (2011), 677–683.
8. Paton, N.I., Goodall, R.L., Dunn, D.T., et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomised controlled trial. JAMA 308 (2012), 353–361.